- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
March 1st, 2012
Using a mouse model of pancreatic ductal adenocarcinoma, Kristopher K. Frese, Ph.D., and colleagues from the University of Cambridge in the United Kingdom, investigated the efficacy and mechanism of action of nanoparticle albumin-bound-paclitaxel combined with gemcitabine.
The researchers found that the combination treatment led to greater tumor regression and reduced tumor metastasis compared with gemcitabine alone. The increased efficacy was due to an increase in gemcitabine levels, which was due to a marked decrease in cytidine deaminase, which metabolizes gemcitabine. Paclitaxel degraded cytidine deaminase via reactive oxygen species.
"These data uncover novel insight into the antitumor activity of nanoparticle albumin-bound-paclitaxel and provide a distinct mechanism for improving gemcitabine delivery to pancreatic tumors that warrants further investigation in the clinical setting," Frese and colleagues conclude.
|Related News Press|
News and information
New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015
Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015
Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015
New technique speeds nanoMRI imaging: Multiplexing technique for nanoscale magnetic resonance imaging developed by researchers in Switzerland cuts normal scan time from two weeks to two days May 28th, 2015